Evaluating symptom severity and urinary cytokine levels in interstitial cystitis/bladder pain syndrome patients, with and without Hunner's lesions
- PMID: 38736620
- PMCID: PMC11087211
- DOI: 10.62347/BLED2401
Evaluating symptom severity and urinary cytokine levels in interstitial cystitis/bladder pain syndrome patients, with and without Hunner's lesions
Abstract
Purpose: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition characterized in part by urinary urgency, frequency, and pain. There is a strong interest in gathering more data to compare and assess the differences in characteristics based on the presence of Hunner's lesions in patients with IC/BPS.
Materials and methods: Using a nationwide crowdsource effort, we collected surveys and urine samples from patients with a history of IC/BPS. Participants completed the Interstitial Cystitis Symptom Index (ICSI) and Problem Index (ICPI), Overactive Bladder questionnaire (OABq SF), and pain scores. In addition, participants reported any co-morbidities and lifestyle modifications. Urinary cytokine levels were measured and compared to symptom severity.
Results: 491 participants enrolled: 119 with history of ulcerative Hunner's lesions (UIC), 372 reported no lesions (NHIC), and 2 unknowns. 96.3% were female, and prevalence of UIC was equal for both genders. Average age was higher for UIC vs. NHIC group (P = 0.011), as was the duration since diagnosis (P < 0.001). Symptom scores were elevated in UIC patients (P < 0.001). Both groups widely implemented lifestyle modifications, with dietary changes being most prevalent (70.1%), followed by prescription medication usage (63.1%). More UIC compared to NHIC participants experienced co-morbidities (P = 0.010). Urine samples were analyzed for GRO, IL-6, IL-8, and MCP-1. MCP-1 levels were significantly higher in UIC patients (P = 0.044). Weak positive correlation was found between cytokines and symptom scores.
Conclusions: Patients with UIC and NHIC from across the United States displayed distinct phenotypic and urine biological characteristics. These findings contribute to increased understanding of IC/BPS and may aid in improving our knowledge of the condition.
Keywords: Urine; biomarker; bladder; inflammation; interstitial cystitis.
AJCEU Copyright © 2024.
Conflict of interest statement
MBC has intellectual property associated with methods for diagnosing interstitial cystitis.
Figures
Similar articles
-
Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.Int J Mol Sci. 2022 Oct 10;23(19):12044. doi: 10.3390/ijms231912044. Int J Mol Sci. 2022. PMID: 36233356 Free PMC article.
-
Does repeated hydrodistension with transurethral fulguration for interstitial cystitis with Hunner's lesion cause bladder contraction?Arab J Urol. 2019 Apr 8;17(1):77-81. doi: 10.1080/2090598X.2019.1589753. eCollection 2019 Mar. Arab J Urol. 2019. PMID: 31258947 Free PMC article.
-
Unsupervised Machine Learning Reveals a Vulvodynia-Predominant Subtype in Bladder Pain Syndrome/Interstitial Cystitis.Cureus. 2024 Jun 18;16(6):e62585. doi: 10.7759/cureus.62585. eCollection 2024 Jun. Cureus. 2024. PMID: 39027744 Free PMC article.
-
Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan.Low Urin Tract Symptoms. 2024 Jan;16(1):e12508. doi: 10.1111/luts.12508. Epub 2023 Nov 21. Low Urin Tract Symptoms. 2024. PMID: 37987028 Review.
-
Cystoscopic characteristic findings of interstitial cystitis and clinical implications.Tzu Chi Med J. 2023 Aug 22;36(1):30-37. doi: 10.4103/tcmj.tcmj_172_23. eCollection 2024 Jan-Mar. Tzu Chi Med J. 2023. PMID: 38406570 Free PMC article. Review.
Cited by
-
Clinical presentation of PD-1/PD-L1 immune checkpoint inhibitors induced cystitis.Invest New Drugs. 2025 Jul 8. doi: 10.1007/s10637-025-01563-2. Online ahead of print. Invest New Drugs. 2025. PMID: 40629252
-
The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome.Biomedicines. 2024 Sep 10;12(9):2051. doi: 10.3390/biomedicines12092051. Biomedicines. 2024. PMID: 39335564 Free PMC article. Review.
-
Using Urine Biomarkers to Differentiate Bladder Dysfunctions in Women with Sensory Bladder Disorders.Int J Mol Sci. 2024 Aug 29;25(17):9359. doi: 10.3390/ijms25179359. Int J Mol Sci. 2024. PMID: 39273307 Free PMC article.
References
-
- Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MJ, Clemens JQ. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. J Urol. 2013;189:141–145. - PMC - PubMed
-
- Hanno PM, Erickson D, Moldwin R, Faraday MM American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–1553. - PubMed
-
- Chancellor MB, Bartolone SN, Veerecke A, Lamb LE. Crowdsourcing disease biomarker discovery research: the IP4IC study. J Urol. 2018;199:1344–1350. - PubMed
-
- Clemens JQ, Mullins C, Kusek JW, Kirkali Z, Mayer EA, Rodriguez LV, Klumpp DJ, Schaeffer AJ, Kreder KJ, Buchwald D, Andriole GL, Lucia MS, Landis JR, Clauw DJ MAPP Research Network Study Group. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol. 2014;14:57. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous